Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.41 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | CYCS | P99999 | 3/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429223 | 0.87 | TOP1 (0.48) | TERTTOP1CYCSABCG2ENPP2 | |
| SCHEMBL21919661 | 0.78 | LMNA (0.39) | TOP1MAOALMNASMN1; SMN2NPSR1 | |
| SCHEMBL18510097 | 0.78 | CYCS (0.41) | TERTTOP1CYCSABCG2ENPP2 | |
| SCHEMBL498495 | 0.76 | TERT (0.51) | TERTTOP1CYCSABCG2ENPP2 | |
| SCHEMBL29408468 | 0.76 | TERT (0.51) | TERTTOP1CYCSABCG2ENPP2 | |
| SCHEMBL6924219 | 0.74 | STAT3 (0.53) | TERTTOP1CYCSABCG2ENPP2 | |
| SCHEMBL15399779 | 0.74 | TOP1 (0.49) | TOP1CYCSABCG2ENPP2 | |
| SCHEMBL21918940 | 0.74 | MEN1 (0.39) | MAOALMNASMN1; SMN2NPSR1 | |
| SCHEMBL21919662 | 0.74 | TYMS (0.39) | TERTMAOALMNASMN1; SMN2NPSR1 | |
| SCHEMBL18510103 | 0.72 | KDM4E (0.34) | TERTENPP2MAOALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130315989-A1 | METHOD FOR TREATING A PATIENT VIA PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2013-11-28 | — | — | US | disclosed |
| US-20120045516-A1 | COMPOSITION FOR PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315989-A1 | METHOD FOR TREATING A PATIENT VIA PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE | TYR, CD47, PPOX | TERT 351/4885TOP1 694/4885CYCS 2210/4885 |
| US-20120045516-A1 | COMPOSITION FOR PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE | APC, TYR, CD47 | TERT 481/4885TOP1 1623/4885CYCS 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.